# A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

> **NCT06531395** · PHASE2 · TERMINATED · sponsor: **Kiniksa Pharmaceuticals International, plc** · enrollment: 3 (actual)

## Conditions studied

- Sjögrens Disease

## Interventions

- **DRUG:** Abiprubart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06531395
- **Lead sponsor:** Kiniksa Pharmaceuticals International, plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-07-17
- **Primary completion:** 2025-03-06
- **Final completion:** 2025-05-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Terminated due to strategic business decision.
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531395, "A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06531395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*